Table 1

Demographic and clinical parameters for the entire patient group, as well as separately for patients who showed clinical disease progression and those who did not

Whole group (n=54)No progression (n=25)Progression (n=29)p Value
Age (years)35 (29; 44)33 (28; 38)39 (31; 47)NS
Sex (M/F)23/316/1917/120.01*
Onset (RO/PO)43/1124/119/100.06*
Disease duration (years)1.4 (0.5; 3.6)1.3 (0.5; 3.3)1.5 (0.6; 4.0)NS
DMT (yes/no)14/407/187/22NS*
EDSS baseline2.0 (2.0; 3.0)2.0 (1.7; 3.0)2.5 (2.0; 3.0)NS
EDSS 2 years2.5 (2.0; 3.5)2.0 (1.5; 2.5)3.0 (2.5; 4.0)<0.001
EDSS 5.5 years3.2 (2.0: 4.7)2.0 (2.0: 3.0)4.0 (3.2; 6.0)<0.001
Progression rate (change EDSS/year)0.2 (0; 0.4)0.0 (0; 0.1)0.4 (0.2; 0.6)<0.001
  • Data are presented as median (IQR). Progression is increase in EDSS of at least 1 point; p value is p value for comparison between progressing and non-progressing patients performed using the Mann–Whitney U test, apart from comparisons marked with *, where the Pearson χ2 test was used; IQR 25%–75%.

  • DMT, numbers are numbers of patients who did (‘yes’) and did not (‘no’) receive disease modifying therapy at any time during the 5.5 year follow-up period; EDSS, Expanded Disability Status Scale; PO, progressive onset; RO, relapse onset.